Introduction {#S0001}
============

Exon 19 deletion and point mutation in L858R are the most common somatic activating mutations in the gene encoding epidermal growth factor receptor (*EGFR*) that confers sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).[@CIT0001],[@CIT0002] However, patients with advanced-stage NSCLC harboring *EGFR* TKI-sensitive mutations may develop progressive disease after a median response period of 12 months, mainly owing to the acquired resistance to EGFR-TKIs through secondary mutations.[@CIT0003]

Substitution of the putative gatekeeper threonine residue at position 790 with methionine (T790M) within exon 20 of *EGFR*, the most frequently reported secondary mutation, accounts for approximately half of the acquired resistance to EGFR-TKIs.[@CIT0004]--[@CIT0006] T790M mutation enhances the ATP-binding affinity of *EGFR*-mutated cells.[@CIT0007],[@CIT0008] As both first- and second-generation TKIs are competitive ATP inhibitors, their efficacy is decreased in the presence of T790M mutation.[@CIT0009]

Although *EGFR* T790M mutation is common after the development of resistance to EGFR-TKI treatment in patients with NSCLC, T790M is still uncommon in unselected patients with NSCLC at diagnosis. Considering that an estimated 1% of *EGFR*-mutant lung cancers harbor T790M mutations at diagnosis,[@CIT0010]--[@CIT0013] approximately 20,996 patients annually diagnosed in the world with lung cancers are thought to carry de novo*EGFR* T790M mutations.[@CIT0014] However, the *EGFR* T790M mutation rate and the clinicopathological features related to its likelihood before treatment remain unknown in Chinese patients. In the present study, we report the clinicopathological and imageological characteristics and clinical outcomes of patients suffering from NSCLC with pretreatment T790M mutation in tumors.

Materials And Methods {#S0002}
=====================

Patient Population {#S0002-S2001}
------------------

A total of 16,347 patients diagnosed with NSCLC were recruited from the Shanghai Pulmonary Hospital affiliated to Tongji University in China between February 2013 and December 2017. All patients were diagnosed with NSCLC and their tumors were genotyped for *EGFR* mutations. Patients were grouped into two populations based on the status of *EGFR* T790M mutation as follows: (1) *EGFR* T790M-positive group and (2) *EGFR* T790M-negative group. All patients provided a written informed consent. The study was approved by the institutional review board at the Shanghai Pulmonary Hospital (Institutional number of ethics consent: K16-257) and was conducted in accordance with the Declaration of Helsinki.

Candidate Gene Mutation Analysis {#S0002-S2002}
--------------------------------

The Amplification Refractory Mutation System (ARMS) was used as the molecular diagnostic method in our study. Between February 2013 and December 2015, genomic DNA and total RNA were extracted from fresh tissues using the QIAamp DNA Tissue Kit and RNeasy Kit (Qiagen, Germany), respectively. Mutations in the *EGFR* and *KRAS* genes and the echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (*EML4-ALK*) rearrangement were detected with Amoy Diagnostics Kits (Xiamen, China) as per the manufacturer's protocol.[@CIT0015] Between January 2016 and December 2017, DNA and total RNA were extracted from five serial slices of a 5-μm paraffin section using the DNA FFPE Tissue Kit and RNeasy Kit (Qiagen, Germany). Mutations in *EGFR* and *KRAS* genes as well as *EML4-ALK* rearrangement were detected according to the manufacturer's protocol of the ACCB Diagnostics Kits (Beijing, China).[@CIT0016] The test could detect mutations at a sensitivity of 1% with no less than 5 ng/μL of DNA sample.

Clinical Assessment {#S0002-S2003}
-------------------

Patient characteristics at the time of lung cancer diagnosis, including age, gender, smoking status, tumor size, pathological TNM stage, tumor morphology, location, histological type, internal structure, lobulation, margin, shape, spiculation, and texture, were retrospectively collected. Smoking status is divided into current smoker, previous smoker, and never smoker. Current smokers are defined as people who reported smoking at least 100 cigarettes during their lifetime and who, at the time they participated in a survey about this topic, reported smoking in the last days. Previous smokers are defined as people who have smoked greater than 100 cigarettes in their lifetime but have not smoked in the last 28 days. Never smokers are defined as people who have not smoked greater than 100 cigarettes in their lifetime and do not currently smoke. Recurrence-free survival (RFS) was calculated from the date of surgical resection until the date of confirmed recurrence from any cause. Patients that were alive at the time of analysis were censored at the last known date of follow-up. All the patients had surgery and were followed-up for more than 12 months.

Statistical Analysis {#S0002-S2004}
--------------------

We compared the clinicopathological features of patients harboring *EGFR*-T790M mutations with patients harboring T790M-negative mutations. The T790M-negative population used for clinicopathological features analysis was consecutively collected at our department from 1st January 2015 to 16th January 2015.[@CIT0017] The RFS for T790M-negative patients were chosen from those that underwent surgery on the same day as the T790M-positive patients or with the surgery time closest to that of T790M-positive patients. No differences in the clinicopathological features were detected between those two T790M-negative populations ([[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=216721.xlsx)]{.ul}). Statistically significant differences in categorical variables between groups were analyzed with the Χ^2^ tests or Fisher's exact test as appropriate. RFS was estimated by the Kaplan--Meier method, and the log-rank test was used for univariate analysis. Cox-proportional hazard model was used for multivariate analysis. The covariates considered for multivariate analysis were gender, aging, TNM stage, tumor size, and smoking. Two-sided values of *P* \< 0.05 were considered statistically significant. SPSS version 20.0 for Windows (IBM SPSS Statistics, Chicago, IL) was used for statistical analyses.

Results {#S0003}
=======

Distribution Of T790M Mutation {#S0003-S2001}
------------------------------

Of 16,347 patients with NSCLC, 7687 with *EGFR* mutations were included in the analysis. All the cases were EGFR-TKI-naïve patients with NSCLC. The uncommon T790M mutation was identified in 106 patients, which corresponded to 1.39% of the patients with *EGFR* mutations ([Figure 1A](#F0001){ref-type="fig"}). *EGFR* L858R mutation and 19-del mutation comprised 48.34% and 41% of all *EGFR* mutations, respectively. The dual 19-del and L858R mutations were observed in 44 (0.57%) patients. Other uncommon *EGFR* mutations observed in the cohort included 139 (1.81%) cases of L861Q mutations, 158 (2.06%) cases of G719X mutations, and 223 (2.9%) cases with 20-ins.Figure 1Schematic view of the frequency of *EGFR* mutations. (**A**) Comprehensive view of *EGFR* mutations and (**B**) distribution of T790M mutation.

*EGFR* T790M mutations were observed in 106 patients. As listed in [Figure 1B](#F0001){ref-type="fig"}, only 11 (10.38%) of all patients with T790M mutations showed single T790M mutation, while 65 (61.32%) patients were positive for dual L858R and T790M mutations and 26 (24.53%) patients showed dual 19-del and T790M mutations. In addition, 1 (0.94%) patient each showed dual L861Q and T790M mutations and dual G719X and T790M mutations, while 2 (1.89%) patients were positive for multiple 19-del, L858R, and T790M mutations.

Clinicopathological Characteristics {#S0003-S2002}
-----------------------------------

T790M mutation was identified in 106 patients, but 4 patients were excluded owing to the lack of clinicopathological information. The clinical characteristics of 102 T790M-positive and 105 T790M-negative cases are summarized in [Table 1](#T0001){ref-type="table"}. No differences were observed in sex, histology, adenocarcinoma subtype, visceral pleura invasion, TNM stage, tumor size, site, and *KRAS* mutation between the two groups. However, the proportion of females was higher in T790M-positive group than in T790M-negative group, although no statistical significance was observed (*P* = 0.092). The incidence of *EML4-ALK* mutation was significantly higher in T790M-positive group than in T790M-negative group (*P* = 0.05), indicating that *EML4-ALK* mutation occurred more frequently in *EGFR* T790M-positive patients.Table 1The Clinicopathological Characteristics Of 207 Patients With NSCLCT790M Positive (%)T790M Negative (%)*P*SexTotal102105p=0.092 Female58 (56.9)49 (46.7) Male44 (43.1)56 (53.3)AgeTotal102105p=0.514 ≤6042 (41.2)44 (41.9) \>6060 (58.8)61 (58.1)SmokingTotal94101p=0.429 Non-smoker79 (84)82 (80.2) Previous smoker5 (5.3)3 (3) Current smoker10 (10.7)16 (16.8)HistologyTotal98105p=0.353 Adenocarcinoma76 (77.6)78 (74.4) Non-adenocarcinoma22 (22.4)27 (25.6)Adenocarcinoma subtypeTotal7568p=0.144 PPA15 (20)5 (7.4) LPA19 (25.3)24 (35.3) PAP37 (49.3)36 (52.9) SPA4 (5.3)3 (4.4)Visceral pleura invasionTotal6768p=0.270 Invaded11 (16.4)15 (22) Close to56 (83.6)53 (78)TNM stageTotal102104p=0.436  IA60 (58.8)52 (50) IB-IIIA42 (41.2)52 (50)Tumor sizeTotal96104p=0.435 ≤3cm71 (74)79 (76) \>3cm25 (26)25 (24)SiteTotal102103p=0.263 Left45 (44)51 (49.5) Right57 (56)52 (50.5)KRASTotal91105p=0.232 Wild type90 (98.9)101 (96.2) Mutation1 (1.1)4 (3.8)EML4-ALKTotal99105p=0.05 Wild type93 (93.9)104 (99) Translocation6 (6.1)1 (1)

To investigate the clinical significance of T790M mutation, we stratified 102 T790M-positive patients into three groups on the basis of single or dual T790M mutations. As shown in [Table 2](#T0002){ref-type="table"}, no differences in age, sex, adenocarcinoma subtype, visceral pleura invasion, TNM stage, site, *KRAS* mutation, and *EML4-ALK* mutation were observed among the three groups. However, the number of patients with tumor size less than 3 cm was higher in dual T790M and L858R mutations group than in single T790M mutation group, although no statistical significance was achieved (*P* = 0.079). The number of patients that never smoked was significantly higher in T790M mutation group than in dual T790M and L858R mutations group (*P* = 0.042). The ratio of adenocarcinoma was significantly higher in dual*EGFR* mutations group than in single T790M mutation group, indicating that the frequency of single T790M mutation was lower in patients with adenocarcinoma.Table 2The Clinicopathological Characteristics In Patients With T790M-Positive MutationT790M (%)T790M/19-del (%)T790M/L858R (%)*P* (T VS T/19)*P* (T VS T/L)*P* (T/LVS T/19)SexTotal112263p=0.270p=0.147p=0.461 Female4 (36.4)12 (54.5)37 (58.7) Male7 (63.6)10 (45.5)26 (41.3)AgeTotal112263p=0.532p=0.645p=0.461 ≤605 (45.5)10 (45.5)26 (41.3) \>606 (54.5)12 (54.5)37 (58.7)SmokingTotal102163p=0.108p=0.042p=0.066 Non-smoker5 (55.6)17 (81)51 (80.9) Previous smoker1 (11.1)3 (14.3)6 (9.5) Current smoker3 (33.3)1 (4.7)6 (9.5)HistologyTotal112161p=0.006p=0.001p=0.066 Adenocarcinoma4 (36.4)20 (95.2)49 (80.3) Non-adenocarcinoma7 (63.6)1 (4.8)12 (19.7)Adenocarcinoma subtypeTotal41949p=0.105p=0.225p=0.144 PPA02 (10.5)13 (26.5) LPA3 (75)3 (15.8)13 (26.5) PAP1 (25)12 (63.2)22 (44.9) SPA02 (10.5)1 (2)Visceral pleura invasionTotal51447p=0.782p=0.582p=0.414 Invaded1 (20)3 (21.4)7 (14.9) Close to4 (80)11 (78.6)40 (85.1)TNM stageTotal111960p=0.4250.548p=0.223 IA7 (63.6)13 (68.4)33 (55) IB-IIIA4 (36.4)6 (31.6)27 (45)Tumor sizeTotal112062p=0.197p=0.079p=0.208 ≤3cm6 (54.5)17 (85)45 (72.6) \>3cm5 (45.5)3 (15)17 (27.4)SiteTotal112263p=0.205p=0.267p=0.581 Left3 (27.3)10 (45.5)29 (46) Right8 (72.7)12 (54.5)34 (54)KRASTotal102058p=0.333p=0.274p=0.774 Wild type9 (90)20 (100)57 (98.3) Mutation1 (10)01 (1.7)EML4-ALKTotal112163p=0.781p=0.482p=0.386 Wild type10 (90.9)20 (95.2)60 (95.2) Translocation1 (9.1)1 (4.8)3 (4.8)[^2]

Patient Imageological Characteristics {#S0003-S2003}
-------------------------------------

The imageological characteristics of patients with NSCLC were analyzed with respect to internal structure, margin, shape, texture, and presence of lobulation and spiculation.[@CIT0018]--[@CIT0022] These characteristics of 102 T790M-positive and 105 T790M-negative patients are shown in [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=216721.xlsx)]{.ul}. No differences in internal structure, margin, spiculation, and texture were detected between the two groups. The proportion of marked lobulation (*P* = 0.025) and shape irregularity (*P* = 0.047) was significantly higher in T790M-positive group than in T790M-negative group.

For T790M-positive cases, no differences in internal structure, margin, shape, texture, and presence of lobulation were reported among the three groups ([[Table S3](https://www.dovepress.com/get_supplementary_file.php?f=216721.xlsx)]{.ul}). The percentage of cases with spiculation was higher in the single T790M mutation group than in dual T790M and L858R mutations group, although the difference was not statistically significant (*P* = 0.073). However, the proportion of spiculation was significantly higher in single T790M mutation group than in the group with dual T790M and 19-del mutations (*P* = 0.005) as well as in dual T790M and L858R mutations group than in dual T790M and 19-del mutations group (*P* = 0.039).

Analysis Of RFS {#S0003-S2004}
---------------

Kaplan--Meier analysis revealed the significantly shorter median RFS for patients with *EGFR* T790M mutations than for those without T790M mutations (odds ratio \[OR\] 3.37, 95% confidence interval \[CI\] 1.67--6.79, *P* = 0.001, [Figure 2A](#F0002){ref-type="fig"}). We divided patients into the following two subgroups to investigate the effects of *EGFR* T790M on *EGFR*-sensitive mutations: *EGFR* 19-del mutation group and *EGFR* L858R mutation group. Of 44 patients with *EGFR* 19-del mutations, 17 with de novo T790M showed significantly shorter RFS than the 27 patients without T790M (OR 2.89, 95% CI 1.10--7.91, *P* = 0.028, [Figure 2B](#F0002){ref-type="fig"}). Similarly, 54 patients with de novo T790M experienced a significantly shorter RFS than the 27 patients without T790M in *EGFR* L858R mutation cohort (OR 3.43, 95% CI 1.33--8.88, *P* = 0.013, [Figure 2C](#F0002){ref-type="fig"}). In addition, we stratified all T790M-positive patients into two subgroups based on their need for adjuvant therapy after surgery ([Figure 3A](#F0003){ref-type="fig"} and [B](#F0003){ref-type="fig"}). The RFS of patients in stage IA group (no specific treatment) (OR 5.18, 95% CI 1.22--10.98, *P* = 0.008, [Figure 3A](#F0003){ref-type="fig"}) and stage IB-IIIA group (adjuvant therapy) (OR 2.56, 95% CI 1.15--5.67, *P* = 0.045, [Figure 3B](#F0003){ref-type="fig"}) with T790M mutation was significantly shorter than that of patients without T790M mutations. In multivariate analysis, patients with *EGFR* T790M mutation tended to have a shorter RFS than those without T790M mutation, although no statistical significance was achieved (hazard ratio \[HR\] 1.64, *P* = 0.123, [Table 3](#T0003){ref-type="table"}). The presence of de novo T790M mutation emerged as a marker of shorter RFS upon coexistence with L858R mutation (HR 3.53, *P* = 0.043, [Table 3](#T0003){ref-type="table"}). Our data indicate that de novo*EGFR* T790M mutation may serve as a poor prognostic indicator for patients with *EGFR*-activating mutations in terms of RFS.Table 3Multivariate Analysis For Recurrence-Free SurvivalOR (95% CI)Regression Coefficient*P*All1.64 (0.88--3.07)0.4940.123L858R3.53 (1.04--11.94)1.260.04319-del2.104 (0.76--5.84)0.7440.153 Figure 2Kaplan--Meier curves of recurrence-free survival (RFS) according to *EGFR* T790M mutation status in patients with NSCLC. *P* value for the difference between the two curves was determined by the log-rank test. (**A**) RFS for both *EGFR* T790M-negative and -positive population. (**B**) RFS for patients with *EGFR* 19-del mutation and *EGFR* 19-del and T790M mutations. (**C**) RFS for patients with *EGFR* L858R mutation and *EGFR* L858R and T790M mutations.Figure 3Kaplan--Meier curves of RFS according to adjuvant therapy status in postoperative patients with NSCLC. (**A**) RFS for both *EGFR* T790M-negative and -positive population with stage IA NSCLC. (**B**) RFS for both *EGFR* T790M-negative and -positive population with stage IB--IIIA NSCLC.

Metastasis Of Patients {#S0003-S2005}
----------------------

As shown in [Figure 4](#F0004){ref-type="fig"}, the presence of T790M mutation correlated with the number of metastatic organs. The proportion of patients with more than two metastatic sites was significantly greater in T790M-positive group than in T790M-negative group (*P* = 0.039). We divided all T790M-positive patients into two groups based on the status of concurrent *EGFR* mutation (19-del or L858R mutation). Patients with dual*EGFR* L858R and T790M mutations tended to display a higher incidence of multiple site metastases than those with single L858R mutation, although no statistical significance was found (*P* = 0.075). No difference in single metastatic site (brain, bone, lung) was observed between T790M-positive and T790M-negative cohorts.Figure 4Corresponding metastatic sites of each patient. 1--9, patients with *EGFR* dual 19-del and T790M mutations; 10--14, patients with 19-del mutation; 15--23, patients with dual L858R and T790M mutations; 24--26, patients with L858R mutations; 27--28, patients with WT *EGFR.*

Discussion {#S0004}
==========

T790M mutation is not only a resistant mechanism but also a clinically significant biomarker following acquired resistance to EGFR-TKIs. Several reports have considered T790M as a favorable prognostic marker after acquired resistance.[@CIT0013],[@CIT0023]--[@CIT0025] Researchers have explored the relationship between prognosis and de novo T790M mutation.[@CIT0025]--[@CIT0030] However, these previous studies have been carried out with a relatively small number of cases; hence, the information provided is limited. In the present study, we comprehensively analyzed the clinicopathological and imageological characteristics and clinical outcomes in a larger cohort of patients with NSCLC, especially in patients with early-stage NSCLC harboring de novo T790M mutation and determined the correlation between pretreatment T790M mutation status and clinical outcomes.

Pretreatment T790M mutation was reported in 1.39% of the patients and coexisted with an *EGFR*-activating or uncommon mutation, consistent with the findings of previous studies.[@CIT0010],[@CIT0012],[@CIT0013] This observation suggests no selection bias in the study cohorts. Pretreatment *EGFR* T790M mutation was reported to be relatively frequent (95/106; 89.62%) in patients carrying concomitant sensitive *EGFR* mutations. As T790M mutation is weakly oncogenic by itself, its oncogenic potential is greatly enhanced in combination with another common *EGFR*-activating mutation such as L858R.[@CIT0011] Our data demonstrated that the frequency of de novo T790M mutation in patients with NSCLC harboring dual*EGFR* T790M and L858R mutations was almost 2.5 times higher (65 vs 26) than that in patients harboring dual*EGFR* T790M and 19-del mutations, consistent with the previous reports.[@CIT0023],[@CIT0027],[@CIT0031]

Here we showed that the incidence of *EML4-ALK* mutation was significantly higher in T790M-positive group than in T790M-negative group, indicating that *EML4-ALK* mutation occurred more frequently in *EGFR* T790M-positive NSCLC patients. The combination of T790M and *EML4-ALK* mutations may synergistically enhance the oncogenic potential of both mutations. A recently published review article suggested that the coexistence of *EML4-ALK* and T790M mutations may serve as a mechanism of resistance to third-generation TKIs,[@CIT0032] paving a way for the development of dual ALK/EGFR inhibitors.[@CIT0033]

Evaluation of clinicopathological characteristics revealed the absence of any association between pretreatment T790M mutation and the majority of the clinicopathological characteristics such as age, stage, tumor size, or tumor site, consistent with the previously reported results.[@CIT0034] We also found that the single T790M mutation was more frequent in females, non-smokers, and non-adenocarcinoma patients than in males, smokers, and adenocarcinoma patients. In combination with T790M mutation, the dual*EGFR* mutations such as single-activating *EGFR* mutation were more likely to be detected in lung adenocarcinoma than in non-adenocarcinoma.[@CIT0001],[@CIT0024],[@CIT0035],[@CIT0036]

Imageological characteristics of T790M-positive and T790M-negative patients are yet incompletely established. We observed that T790M-positive patients presented marked lobulation and irregular shape. Given the limited number of patients with *EGFR* T790M mutation, we failed to establish imageological characteristics of patients with single T790M mutation that warrants further studies.

T790M mutation conferred additional transforming properties in combination with the common *EGFR*-activating mutations and significantly affected the RFS. In our study, the presence of de novo T790M mutation correlated with reduced RFS in patients with NSCLC in combination with an *EGFR*-activating mutation, indicating that *EGFR* T790M mutation may serve as a poor prognostic indicator for patients with *EGFR-*activating mutation in terms of RFS. The presence of de novo T790M mutation was associated with inferior RFS in patients with NSCLC that accepted adjuvant therapy after surgery.

The presence of T790M mutation also correlated with tumor metastatic capability. The proportion of patients with more than two metastatic sites was significantly higher in T790M-positive group than in T790M-negative group (*P* = 0.039). Patients with dual*EGFR* L858R and T790M mutations tended to exhibit a higher incidence of multiple site metastases than those with single L858R mutation, although no statistical significance was reported (*P* = 0.075).

The role of T790M mutation in lung cancer progression, especially before TKIs treatment, is still being debated. Yosuke Togashi et al demonstrated that the inhibition of β-catenin signal-mediated cancer stem cell-like properties resulted in an increase in the anticancer effects of irreversible EGFR-TKIs in *EGFR*-mutated NSCLC carrying T790M mutation.[@CIT0037] Thus, the stemness of cancer cells carrying dual*EGFR*-activating mutation and T790M mutation may contribute to the progression of disease. The activation of cell growth, proliferation, or apoptosis-related signaling pathways may also explain the worse RFS in patients with NSCLC harboring pretreatment concomitant *EGFR* T790M mutation. Co-targeting EGFR and signaling proteins, such as Src,[@CIT0038] Orphan receptor 1 (ROR1),[@CIT0039] and vascular endothelial cell growth factor (VEGF),[@CIT0040] showed a significant synergistic effect by overcoming or delaying the resistance to EGFR inhibitors in pre-clinical and clinical studies. It is unclear whether patients harboring pretreatment T790M mutation will benefit more from third-generation EGFR-TKIs than those without pretreatment T790M mutation. Several ongoing clinical trials may help researchers explore this important issue.[@CIT0041]--[@CIT0044]

Our study has several limitations. First, despite the inclusion of larger-scale data than previous studies, the results were produced from the patients at a single institution. Second, as this was a retrospective study, we failed to analyze non-tumor tissues to rule out the effects of germline T790M mutation. Third, the prevalence of pretreatment T790M mutation varied with analyses using different detection methods and ranged from 0.5% to 79%.[@CIT0025],[@CIT0028],[@CIT0045]--[@CIT0047] The frequency of T790M mutation was 1.39%, consistent with the results of a study from another center in China.[@CIT0048] Different detection and sampling methods led to the differences in prevalence rates, owing to variations in sensitivity and specificity. We evaluated *EGFR* mutation status by ARMS. ARMS use specific primer that binds with a target sequence during the annealing step to enrich the sequence, which can achieve a higher specificity. *EGFR* T790M mutation is a somatic mutation, mutant cells are usually mixed with wild type cells; thus, the extracted DNA often has a large amount of wild type DNA, and so the detection of such somatic mutation needs higher specificity. Taken together, ARMS is one of the best options for T790M detection after balancing sensitivity and specificity.

Conclusion {#S0005}
==========

The presence or absence of *EGFR* T790M mutation confers different disease characteristics and prognosis. We analyzed the clinicopathological characteristics of pretreated patients with NSCLC harboring de novo T790M mutations and determined the correlation between T790M mutation status and clinical outcomes. Our results indicate that the pretreatment T790M mutation tended to affect the imageological characteristics of NSCLC and that the presence of T790M mutation was associated with poor prognosis of patients with NSCLC.
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